GLP-1 Market
LLY $1184.63 ▼ -0.0% NVO $38.31 ▼ -1.0% PFE $28.72 • 0.0% VKTX $31.81 ▼ -3.7% KLRA $10.99 ▼ -1.2% GPCR $32.69 ▼ -6.8% RHHBY $52.25 ▼ -2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HS235

HS235

Company
35Pharma Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Find a Clinical Trial Near Me

See recruiting studies for HS235 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07123779

    HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

    Not yet reported, Not yet reported 35Pharma Inc 126 participants Est. completion 2030-01 2 sites Stand-alone
    Heart failure Other conditions: Pulmonary Hypertension
    View official trial listing →
  • Recruiting NCT NCT07143448

    A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

    Not yet reported, Not yet reported 35Pharma Inc 90 participants Est. completion 2028-11 4 sites Stand-alone
    Other conditions: Pulmonary Arterial Hypertension
    View official trial listing →
  • Completed NCT NCT06714825

    Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

    Not yet reported 35Pharma Inc 39 participants Est. completion 2025-12-02 1 site Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.